Sid Sijbrandij, co-founder of GitLab, embarked on a highly personalized and self-directed cancer treatment journey, termed "Founder Mode," after exhausting standard therapeutic options for his rare T5 osteosarcoma and finding no eligible clinical trials. His approach, documented transparently through osteosarc.com and a 25TB public Google Cloud bucket, aims not only for personal remission but also to develop a scalable patient-driven model to overcome systemic limitations in healthcare.

The core methodology, inspired by the "Founder Mode" philosophy, is structured around three principal tenets:

1. Maximal Diagnostics: This principle emphasizes exhaustive and frequent data acquisition at the deepest possible resolution. It involved:
   • Single-cell sequencing (10x Genomics): To measure cell-type-specific gene expression levels, particularly identifying genetic targets for therapy and performing T-cell receptor (TCR) analysis. This enabled the detection of aberrantly expressed fibroblast markers like KERA, LUM, EPYC, and FAP within tumor cells.
   • Bulk DNA/RNA sequencing: To ascertain the comprehensive mutational landscape of the entire tumor.
   • Minimal Residual Disease (MRD) testing: Utilizing circulating tumor DNA (ctDNA) assays from multiple providers for early detection of recurrence.
   • Organoid assays: Cultivating patient-derived tumor organoids for in vitro drug response prediction.
   • Pathology Stains: To validate promising genomic hypotheses at the tissue level using archived samples.

2. Custom Treatment Development: Based on the rich diagnostic data, Sid collaborated with corporate and academic researchers to develop and identify novel, personalized therapeutic agents. This approach allowed him to access over 10 different experimental treatments.

3. Parallel Treatment: Instead of sequential therapy where a single treatment is pursued until failure, Sid adopted a parallel strategy. Multiple therapeutic hypotheses were tested concurrently, with responses continuously monitored and measured through the comprehensive diagnostic pipeline. This minimized delays and allowed for rapid iteration and adaptation.

A critical turning point in his treatment involved an experimental FAP-targeted radioligand therapy in Germany. Single-cell analysis revealed the overexpression of Fibroblast Activation Protein (FAP) on his tumor cells. This allowed for a precise therapeutic strategy: a ligand targeting FAP was conjugated with a radioisotope. Initially, a "cold" isotope was administered for diagnostic imaging to confirm FAP expression in the tumor. Subsequently, a "hot" therapeutic payload, specifically Lutetium-177 (Lu-177), was delivered. This precision medicine approach, unlike systemic chemotherapy, minimized off-target effects. The treatment successfully reduced the tumor to a resectable size. Post-surgical analysis revealed a significant increase in tumor-infiltrating T-cells (from 19% to 89%), indicating a robust immune response, attributed to a synergistic effect of checkpoint inhibitors, a personalized neoantigen peptide vaccine, oncolytic viruses, and prior radiotherapy.

Beyond the specific treatments, Sid's "Founder Mode" involved building a "care stack," including detailed documentation in "Sid Health Notes" and leveraging private concierge medical services. He also navigated significant systemic barriers, such as resistance from traditional hospitals regarding non-standard sample collection (e.g., cryopreserved samples for single-cell analysis vs. standard FFPE) and access to raw genomic data. He successfully utilized FDA's Form 3926 for individual patient expanded access INDs to receive five experimental therapies, highlighting regulatory flexibility contrasting with institutional review boards' "vetocracy."

The "Founder Mode" advocates for a paradigm shift in healthcare towards patient-centricity and personalized medicine, exemplified by drug repurposing based on deep diagnostic data and the development of entirely new molecularly-targeted therapies. Sid's ongoing journey includes maintaining remission with an mRNA-based personalized neoantigen vaccine and co-developing advanced cell-based therapies with genetic logic gates for future "nuclear option" scenarios. His experience underscores the potential of an empowered patient leveraging technology and data to overcome traditional healthcare limitations, envisioning a future where advanced, personalized diagnostics and therapies are more accessible and affordable, challenging the current "Eroom's Law" of increasing drug development costs.